首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1374781

全球臨床化學分析儀市場 -2023-2030

Global Clinical Chemistry Analyzers Market -2023-2030

出版日期: 2023年11月01日 | 出版商:

DataM Intelligence | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

多年來，全球臨床化學分析儀市場經歷了顯著的成長和轉變，影響其動態的因素有很多。臨床化學分析儀是自動化醫學實驗室設備的重要組成部分。這些設備檢查並表徵生物樣本（例如血液或尿液）的流體樣本成分。可以使用先進的化學或光學方法來做到這一點；不過，稍後會詳細介紹。

政府新產品的推出和研究，特別是在發展中經濟體，將繼續推動先進的全自動臨床生化分析儀或半自動臨床生化分析儀的使用，並推動全球臨床生化分析儀市場的發展。各自的創新化學分析儀有兩種形式，包括桌上型和落地式。

市場動態：促進因素與限制因素

不斷成長的合作和收購

在高投資、收入水準和基礎設施發展的推動下，已開發經濟體的醫療保健產業不斷改善。由於研究的不斷增加，一些國家對臨床化學分析儀的需求量很大。不同國家之間的各種合作、收購和技術進步的產品發布將是推動市場成長的關鍵因素。

2023 年 2 月 2 日，著名醫療設備供應商西門子 Healthineers 和著名診斷服務供應商 Unilabs 啟動了一項價值超過 2 億歐元的多年期安排。 Unilabs 投資了西門子 Healthineers 的尖端技術，並將購買 400 多台科學分析儀，以進一步升級其實驗室基礎設施，並為客戶提供無與倫比的服務。

此外，2021 年 2 月 3 日，HORIBA Instruments 歐文總部和 HORIBA, Ltd. 日本京都總部收購了 MedTest Holdings, Inc.。透過此次收購，HORIBA Medical 將有機會滿足以下行業的多學科需求：進軍IVD 市場，同時利用Pointe Scientific 和MedTest 卓越的化學產品的革命性技術。

此外，新技術和不同類型的臨床化學分析儀也擴大用於多種研究目的。慢性疾病的增加和創新診斷產品開發研究的增加將是推動臨床化學分析儀市場成長的主要因素。

與臨床化學分析儀相關的高成本

儘管試劑盒或消耗品的成本以及 CPRT 的成本是可能影響臨床化學實驗室購買或使用的儀器類型的一些標準，但現代臨床化學實驗室的設備成本價格昂貴。

生化分析儀初期投資較大；頂級型號的售價高達 45,000 美元。由於購買價格高昂，醫院等用戶被迫透過租賃協議購買，降低了銷售額。

有關此報告的更多詳細資訊 - 索取樣本

The global clinical chemistry analyzers market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. Clinical chemistry analyzers are crucial parts of automated medical laboratory equipment. These devices examine and characterize the fluid sample composition of biological samples like blood or urine. Advanced chemical or optical methods can be used to do this; however, more on that in a moment.

Government novel product launch and research, particularly in developing economies, will continue to drive utilization of advanced fully automatic clinical chemistry analyzers or semi-automatic clinical chemistry analyzers and boost the global clinical chemistry analyzers market. The respective innovative chemistry analyzers are in two modalities including bench-top and floor standing.

Market Dynamics: Drivers & Restraints

Growing collaborations and acquisitions

Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high investments, income levels, and infrastructure development. Several countries have experienced substantial demand for clinical chemistry analyzers owing to the rising research. Various collaborations, acquisitions and product launches with technological advanecments among different countries will be a crucial factor driving the growth of the market.

On February 2, 2023, a multi-year arrangement with a value of more than €200 million was started by Siemens Healthineers, a renowned provider of medical equipment, and Unilabs, a renowned supplier of diagnostic services. Unilabs has invested in cutting-edge technology from Siemens Healthineers and will buy more than 400 scientific analyzers to further upgrade its laboratory infrastructure and provide its clients with unmatched service.

Additionally, on February 3, 2021, MedTest Holdings, Inc. has been purchased by the Irvine headquarters of HORIBA Instruments and the Kyoto, Japan headquarters of HORIBA, Ltd. Through this acquisition, HORIBA Medical will have the chance to serve the multidisciplinary needs of the IVD market while utilizing Pointe Scientific's and MedTest's superior Chemistry products' complimentary revolutionary technologies.

Furthermore, the rising utilization of novel technology and different types of clinical chemistry analyzers for the several research purposes. Rising chronic disorders and increasing research for innovative diagnostic product development will be a major factor driving the growth of the clinical chemistry analyzers market.

High cost associated with the clinical chemistry analyzers

Although the cost of kits or consumables, as well as the cost of the CPRT, are some of the criteria that may affect the type of instrument to be purchased or utilized in a clinical chemistry laboratory, the cost of the equipment in modern clinical chemistry laboratories is expensive.

Biochemistry analyzers involve a large initial investment; top-of-the-line models can cost up to $45,000. Because of their high acquisition prices, users like hospitals are forced to purchase them through rental agreements, which lowers sales.

For more details on this report - Request for Sample

Segment Analysis

The global clinical chemistry analyzers market is segmented based on product type, modality, application, end user and region.

Fully Automatic Clinical Chemistry Analyzers segment accounted for approximately 64% of market share

Fully automated chemical analyzers make it easier and more efficient to complete analytical tasks in various laboratory environments. Researchers can get evaluation results from these tools with exceptional precision. Get analysis reports in the shortest amount of time possible. A variety of diagnostic tasks are performed using fully automated chemical analyzers, including routine examination of albumin, glucose, creatinine, bilirubin, or inorganic phosphorus.

These are also employed in the execution of assays for the evaluation of lipids, therapeutic medications, illicit drugs, and more. Fully automated chemistry analyzers make it possible to do a variety of research tasks more quickly and deliver data in the shortest amount of time.

On June 8, 2023, the most recent offering from Mindray is the M1000 Chemistry with Immunoassay Integrated Solution, which combines an intelligent sample delivery module with two cutting-edge analyzers: the Chemiluminescence Immunoassay Analyzer CL-8000i and the state-of-the-art Chemistry Analyzer BS-2800M. Since its introduction, the solution has received a great deal of customer support and appreciation for its high degree of accuracy, effectiveness, and resilience, especially for the creative design and potent features of the experimental treatment system.

Geographical Penetration

North America accounted for around 34% of market share in 2022

Due to the rising need for clinical chemistry analyzers in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for clinical chemistry analyzers.

Increasing expenditure on healthcare and rising research studies, advancement of technologies and different types of products, and increase in biopharmaceutical or biotechnology business establishment across the region are also contributing to the growth of clinical chemistry analyzers market share of this region. The market in this area is growing as people become more aware of various novel innovative products such as fully automatic clinical chemistry analyzers. The aforementioned elements further attest to North America's hegemonic position in the world.

North America continues to be a key player in the global clinical chemistry analyzers market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for clinical chemistry analyzers in the U.S. United States have been proactive in executing several initiatives or researches, stimulating clinical chemistry analyzers demand.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global clinical chemistry analyzers market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of various device designs, was significantly impacted. Several efforts all throughout the world were impacted by the pandemic's broad lockdowns and limitations that started in early 2020.

Major medical and biotechnology industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for clinical chemistry analyzers. Now several research studies have been initiated and companies have again started launching novel products with high efficiency. Overall, the impact of the pandemic on the global clinical chemistry analyzers market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for innovative products, like bench-top analyzers.

Key Developments

On July 25, 2023, the FDA has approved Beckman Coulter Diagnostics' new automated chemistry analyzer, DxC 500 AU Chemistry Analyzer. This decision expands the company's clinical chemistry offering and shows its continued commitment to product innovation in the in vitro diagnostics sector. The DxC 500 AU Chemistry Analyzer, one of several new Beckman Coulter products created to streamline laboratory operations and assist crucial clinical decisions, is intended for small-to-medium-sized laboratories.
On July 2o, 2023, the Atellica CI Analyzer for clinical chemistry testing or immunoassay, the newest addition to Siemens Healthineers' Atellica in vitro diagnostics portfolio, has acquired FDA clearance and is currently offered in many of the major markets across the world. The competitive benefits that the analyzer offers, such as enhanced turnaround time predictability, cutting-edge reporting features, and targeted safety and security measures, will be beneficial to labs operating at low to moderate testing volumes.

Competitive Landscape

The major global players in the market include: F. Hoffmann-La Roche Ltd, Beckman Coulter, Inc., HORIBA Medical, Siemens Healthcare Private Limited, Hitachi High-Tech Corporation, Thermo Fisher Scientific Inc., EKF Diagnostics Holdings plc, Abbott, Mindray Medical India Pvt. Ltd. And Randox Laboratories Ltd. Among others.

Why Purchase the Report?

To visualize the global clinical chemistry analyzers market segmentation based on product type, modality, application, end user and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of clinical chemistry analyzers market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global clinical chemistry analyzers market report would provide approximately 69 tables, 66 figures and 186 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Modality
3.3. Snippet by Application
3.4. Snippet by End User
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Growing collaborations and acquisitions
  - 4.1.1.2. Rising technological advancements and developments
- 4.1.2. Restraints
  - 4.1.2.1. High cost associated with the clinical chemistry analyzers
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. SWOT Analysis
5.6. Patent Analysis
5.7. Russia-Ukraine War Impact Analysis
5.8. DMI Opinion

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Product Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 7.1.2. Market Attractiveness Index, By Product Type
7.2. Fully Automatic Clinical Chemistry Analyzers*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Semi-Automatic Clinical Chemistry Analyzers

8. By Modality

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
- 8.1.2. Market Attractiveness Index, By Modality
8.2. Bench-Top Analyzers*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Floor-Standing Analyzers

9. By Application

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.1.2. Market Attractiveness Index, By Application
9.2. Clinical Diagnostics *
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Drug Testing
9.4. Others

10. By End User

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.1.2. Market Attractiveness Index, By End User
10.2. Hospitals*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Academic or Research Laboratories
10.4. Diagnostic Centers
10.5. Others

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.2.7.1. U.S.
  - 11.2.7.2. Canada
  - 11.2.7.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.3.7.1. Germany
  - 11.3.7.2. UK
  - 11.3.7.3. France
  - 11.3.7.4. Italy
  - 11.3.7.5. Spain
  - 11.3.7.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.4.7.1. Brazil
  - 11.4.7.2. Argentina
  - 11.4.7.3. Rest of South America
11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.5.7.1. China
  - 11.5.7.2. India
  - 11.5.7.3. Japan
  - 11.5.7.4. Australia
  - 11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. Company Profiles

13.1. F. Hoffmann-La Roche Ltd*
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
13.2. Beckman Coulter, Inc.
13.3. HORIBA Medical
13.4. Siemens Healthcare Private Limited
13.5. Hitachi High-Tech Corporation
13.6. Thermo Fisher Scientific Inc.
13.7. EKF Diagnostics Holdings plc
13.8. Abbott
13.9. Mindray Medical India Pvt. Ltd.
13.10. Randox Laboratories Ltd.

LIST NOT EXHAUSTIVE